Table VII.
Associations between long non-coding RNA expression and clinicopathological parameters in 40 patients with high-grade ovarian serous cancer.
| Parameter | Age (years)
|
FIGO stage
|
Lymph node metastasis
|
CA125 level (U/ml)
|
||||
|---|---|---|---|---|---|---|---|---|
| <50 | ≥50 | I-II | III-IV | Negative | Positive | <600 | ≥600 | |
| GTSE1-AS1 | ||||||||
| High no. cases | 6 | 8 | 5 | 4 | 6 | 4 | 10 | 6 |
| Low no. cases | 10 | 16 | 16 | 15 | 17 | 13 | 15 | 9 |
| P-value | 0.548 | <0.01 | <0.01 | 0.432 | ||||
| FAS-AS1 | ||||||||
| High no. cases | 9 | 15 | 17 | 14 | 16 | 12 | 17 | 8 |
| Low no. cases | 7 | 9 | 4 | 5 | 7 | 5 | 8 | 7 |
| P-value | 0.433 | <0.01 | <0.01 | 0.694 | ||||
| AK130076 | ||||||||
| High no. cases | 10 | 16 | 18 | 15 | 18 | 12 | 17 | 10 |
| Low no. cases | 6 | 8 | 3 | 4 | 5 | 5 | 8 | 5 |
| P-value | 0.249 | <0.01 | <0.01 | 0.167 | ||||
| RP11-199F11.2 | ||||||||
| High no. cases | 10 | 15 | 16 | 16 | 20 | 11 | 14 | 9 |
| Low no. cases | 6 | 9 | 5 | 3 | 3 | 6 | 11 | 6 |
| P-value | 0.726 | <0.01 | <0.01 | 0.259 | ||||
| AC093818.1 | ||||||||
| High no. cases | 11 | 14 | 15 | 14 | 17 | 14 | 16 | 8 |
| Low no. cases | 5 | 10 | 6 | 5 | 6 | 3 | 9 | 7 |
| P-value | 0.673 | <0.01 | <0.01 | 0.464 | ||||
FIGO, International Federation of Gynecology and Obstetrics; CA125, cancer antigen 125; GTSE1-AS1, GTSE1 antisense RNA 1 (head to head); FAS-AS1, FAS antisense RNA 1; High no. cases, numbers of specimens with high expression of associated genes in high-grade ovarian serous cancer (compared with the expression level of associated genes in healthy fallopian tube tissue samples); Low no. cases, numbers of specimens with low expression of associated genes in high-grade ovarian serous cancer (compared with the expression level of associated genes in healthy fallopian tube tissue samples).